MOTS-C is studied as a mitochondrial-derived peptide in cellular energy-metabolism, stress-response, and AMPK-pathway models.
- Mitochondrial signaling
- Cellular energy metabolism
- AMPK pathway models
MOTS-C is a mitochondrial peptide, not NAD+
MOTS-C is studied as a mitochondrial-derived peptide in energy-metabolism and AMPK-pathway models. NAD+ is the cofactor listing. SS-31 is the membrane peptide.
Task 193720, batch MC-20, June 22, 2026, prints 23.38 mg and purity 99.198%.
Label versus report
The catalog amount is 20 mg at $64.99. The printed mass is 23.38 mg. Quote both.
This page is laboratory education for adults 21 and older. It is not a dosing guide, a treatment plan, or a ranking of which material to use. Not for human or veterinary use.
MOTS-C 20 mg research questions
What does the MOTS-C report print?
23.38 mg and purity 99.198%, task 193720.
Is this NAD+?
No. NAD+ is 1,000 mg at $84.99.
References and further reading
- PubMed literature index — MOTS-C 20 mg ↗
A continuously updated index of peer-reviewed biomedical literature. Study quality, model, and relevance must be assessed individually.
- FDA — Analytical Procedures and Methods Validation ↗
Regulatory guidance on analytical method development and validation.
- ICH Q2(R2) — Validation of Analytical Procedures ↗
International guidance on specificity, accuracy, precision, range, and robustness.
- Hoofnagle et al. — Recommendations for peptide storage and handling ↗
Peer-reviewed recommendations for peptide handling in quantitative laboratory workflows.
External links are provided for independent literature review. A link does not imply that every indexed paper supports the same conclusion or that findings apply beyond the model and conditions studied.